MX378108B - Anticuerpos anti-met y composiciones. - Google Patents
Anticuerpos anti-met y composiciones.Info
- Publication number
- MX378108B MX378108B MX2017003211A MX2017003211A MX378108B MX 378108 B MX378108 B MX 378108B MX 2017003211 A MX2017003211 A MX 2017003211A MX 2017003211 A MX2017003211 A MX 2017003211A MX 378108 B MX378108 B MX 378108B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- met
- antibodies
- met antibodies
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051190P | 2014-09-16 | 2014-09-16 | |
| PCT/IB2015/002110 WO2016042412A1 (en) | 2014-09-16 | 2015-09-15 | Anti-met antibodies and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003211A MX2017003211A (es) | 2017-06-06 |
| MX378108B true MX378108B (es) | 2025-03-10 |
Family
ID=54780359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003211A MX378108B (es) | 2014-09-16 | 2015-09-15 | Anticuerpos anti-met y composiciones. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10450376B2 (enExample) |
| EP (1) | EP3194444B1 (enExample) |
| JP (1) | JP6927875B2 (enExample) |
| KR (1) | KR102200274B1 (enExample) |
| CN (1) | CN107001471B (enExample) |
| AU (1) | AU2015316522B2 (enExample) |
| CA (1) | CA2961323C (enExample) |
| ES (1) | ES2748295T3 (enExample) |
| IL (1) | IL250902B (enExample) |
| MX (1) | MX378108B (enExample) |
| WO (1) | WO2016042412A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61659B1 (sr) | 2016-05-17 | 2021-04-29 | Abbvie Biotherapeutics Inc | Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu |
| EP3519440A4 (en) | 2016-09-29 | 2020-03-25 | Mitsubishi Tanabe Pharma Corporation | MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| AU2018280485A1 (en) | 2017-06-06 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising c-Met antibody-drug conjugate and use thereof |
| MX2020010110A (es) * | 2018-03-28 | 2020-11-06 | Mitsubishi Tanabe Pharma Corp | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. |
| KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102433184B1 (ko) * | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| CA3143211A1 (en) * | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| WO2021058735A1 (en) | 2019-09-26 | 2021-04-01 | Symphogen A/S | Cancer treatment with anti-met antibody compositions |
| WO2022204332A1 (en) * | 2021-03-24 | 2022-09-29 | Combangio, Inc. | Compositions comprising c-met agonist antibodies and methods for use in ocular treatment |
| AU2022254291A1 (en) | 2021-04-08 | 2023-10-12 | Byondis B.V. | Anti-c-met antibodies and antibody-drug conjugates |
| WO2023150632A2 (en) * | 2022-02-02 | 2023-08-10 | The Broad Institute, Inc. | Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| AU2024277829A1 (en) | 2023-05-19 | 2025-12-04 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| EP0662130B1 (en) | 1992-09-18 | 1997-11-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A method of producing hepatocyte growth factor and a cell line |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| ATE465257T1 (de) | 1996-07-03 | 2010-05-15 | Genentech Inc | Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| US7615529B2 (en) | 2005-03-25 | 2009-11-10 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| WO2007110698A2 (en) | 2005-11-16 | 2007-10-04 | Fariba Nayeri | Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors |
| ES2368864T3 (es) | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| US8133867B2 (en) | 2006-03-20 | 2012-03-13 | Seikagaku Corporation | Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor |
| BRPI0709917A2 (pt) | 2006-03-30 | 2011-07-05 | Novartis Ag | composições e métodos de uso para anticorpos de c-met |
| US8039598B2 (en) | 2007-01-19 | 2011-10-18 | Van Andel Research Institute | Met fab and SCFV fragments |
| BRPI0812091A2 (pt) | 2007-05-25 | 2014-10-14 | Symphogen As | Método para fabricar uma proteína policlonal recombinante |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| RU2010147652A (ru) | 2008-04-23 | 2012-05-27 | Симфоген А/С (Dk) | Способы производства поликлонального белка |
| WO2009142738A2 (en) | 2008-05-21 | 2009-11-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| JP2012504961A (ja) * | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| WO2012059857A2 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Pan-her antibody composition |
| EP3165538A1 (en) * | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
-
2015
- 2015-09-15 MX MX2017003211A patent/MX378108B/es unknown
- 2015-09-15 JP JP2017514687A patent/JP6927875B2/ja active Active
- 2015-09-15 IL IL250902A patent/IL250902B/en unknown
- 2015-09-15 ES ES15804578T patent/ES2748295T3/es active Active
- 2015-09-15 AU AU2015316522A patent/AU2015316522B2/en active Active
- 2015-09-15 EP EP15804578.1A patent/EP3194444B1/en active Active
- 2015-09-15 KR KR1020177010306A patent/KR102200274B1/ko active Active
- 2015-09-15 CA CA2961323A patent/CA2961323C/en active Active
- 2015-09-15 CN CN201580059801.8A patent/CN107001471B/zh active Active
- 2015-09-15 WO PCT/IB2015/002110 patent/WO2016042412A1/en not_active Ceased
- 2015-09-15 US US15/510,545 patent/US10450376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10450376B2 (en) | 2019-10-22 |
| IL250902A0 (en) | 2017-04-30 |
| US20180327500A1 (en) | 2018-11-15 |
| KR102200274B1 (ko) | 2021-01-08 |
| AU2015316522A1 (en) | 2017-03-23 |
| ES2748295T3 (es) | 2020-03-16 |
| CA2961323A1 (en) | 2016-03-24 |
| EP3194444A1 (en) | 2017-07-26 |
| AU2015316522B2 (en) | 2021-01-21 |
| WO2016042412A1 (en) | 2016-03-24 |
| JP6927875B2 (ja) | 2021-09-01 |
| IL250902B (en) | 2022-08-01 |
| KR20170054517A (ko) | 2017-05-17 |
| EP3194444B1 (en) | 2019-07-10 |
| CN107001471B (zh) | 2022-01-18 |
| CA2961323C (en) | 2021-11-30 |
| BR112017005202A2 (pt) | 2017-12-12 |
| CN107001471A (zh) | 2017-08-01 |
| MX2017003211A (es) | 2017-06-06 |
| JP2017534259A (ja) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| NI201700019A (es) | Anticuerpos anti tigit | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| CL2019000779A1 (es) | Anticuerpos anti-cd27. | |
| CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
| MX2020001360A (es) | Macrociclos de diarilo como moduladores de la proteina quinasa. | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| MX369041B (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX385842B (es) | Conjugados de partículas de tipo virus y uso de las mismas. | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
| CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| MX373333B (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina y métodos de uso. |